The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Telisotuzumab vedotin-associated peripheral neuropathy in NSCLC
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses the Phase II LUMINOSITY trial (NCT03539536) of telisotuzumab vedotin, a c-Met–directed antibody-drug conjugate (ADC), in previously treated patients with c-Met protein-overexpressing non-small cell lung cancer (NSCLC). Peripheral neuropathy was a frequent adverse event, typically occurring later during treatment, and occasionally leading to discontinuation. Patients who developed higher-grade neuropathy generally remained on therapy longer and showed improved efficacy outcomes, suggesting an association between treatment duration, cumulative toxicity, and therapeutic benefit. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We are investigating the neuropathy in the teliso-V program. So because we have the teliso-V as a payload of the MMAE, but usually the MMA ADCs which have the MMAE payload, we have a very great problem about the sensory neuropathy. So many questions are coming from the audience about the teliso-V. How the sensory neuropathy is. So we are focused on sensory neuropathy in this program and provided the subgroup analysis listing...
We are investigating the neuropathy in the teliso-V program. So because we have the teliso-V as a payload of the MMAE, but usually the MMA ADCs which have the MMAE payload, we have a very great problem about the sensory neuropathy. So many questions are coming from the audience about the teliso-V. How the sensory neuropathy is. So we are focused on sensory neuropathy in this program and provided the subgroup analysis listing.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
